Background
Mechanism of Action
- Antiviral that targets subunit 2 of the viral terminase complex (UL56) in cytomegalovirus
Spectrum of Activity
- Indications: Cytomegalovirus
- No activity against HSV or VZV
Dosing
- Letermovir 480 mg IV/PO q24h, infused over 1 hour
- If concomitant cyclosporine, decrease dose to 240 mg IV/PO q24h
Renal Dosing
- No dose adjustment needed as long as CrCl >10 mL/min
Safety
Adverse Drug Reaction
- Nausea, vomiting, diarrhea, cough, headache, peripheral edema
Drug-Drug Interactions
- Increases bioavailability of cyclosporine
- Decreases concentration of voriconazole
- Concentration of letermovir is increased by atorvastatin, sirolimus, and tacrolimus
